Table 1.

Phase 3 Interventional clinical studies targeting FGF receptors in cancer. Currently there are no phase 4 clinical trials, however, there are over 90 phase 1 and 2 clinical trials targeting FGFR in different types of cancers, and a number of phase 3 trials not yet recruiting. FGFR inhibitors are indicated in bold.

NCT Number	Title	Conditions	Interventions	Enrolment
NCT03390504	A Study of Erdafitinib compared with Vinflunine or Docetaxel or Pembrolizumab in participants with advanced urothelial cancer and selected Fibroblast Growth Factor Receptor (FGFR) gene aberrations	Urothelial Cancer	Erdafitinib, Vinflunine, Docetaxel, Pembrolizumab	631
NCT04197986	Study of oral Infigratinib for the adjuvant Treatment of subjects with invasive urothelial carcinoma with susceptible FGFR3 genetic alterations	Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer	Infigratinib	218
NCT04093362	Futibatinib versus Gemcitabine-Cisplatin chemotherapy as first-line treatment of patients with advanced cholangiocarcinoma harboring FGFR2 gene rearrangements	Advanced Cholangiocarcinoma; FGFR2 Gene Rearrangements	Futibatinib, Cisplatin/Gemcitabine	216
NCT03773302	Phase 3 study of BGJ398 (Oral Infigratinib) in first line cholangiocarcinoma with FGFR2 gene fusions/translocations	Advanced Cholangiocarcinoma, FGFR2 Gene Mutation	Infigratinib, Gemcitabine, Cisplatin	300
NCT03656536	A study to evaluate the efficacy and safety of Pemigatinib versus chemotherapy in unresectable or metastatic cholangiocarcinoma	Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma	Pemigatinib, Gemcitabine, Cisplatin	432
NCT03784014	Molecular profiling of advanced soft-tissue sarcomas	Soft Tissue Sarcoma	Nilotinib, Ceritinib, Capmatinib, Lapatinib, Trametinib, Combination of Trametinib and Dabrafenib, Combination of Olaparib and Durvalumab, Palbociclib, Futibatinib	960